Abstract
Aim Novel dietary interventions focused on fasting, have gained scientific and public attention. Periodic fasting has emerged as a dietary modification promoting beneficial effects on metabolic syndrome. This study aimed to assess whether periodic fasting reduces albuminuria in patients with type 2 diabetes and diabetic nephropathy and determine whether a reduction in albuminuria relates to activation of nephropathy-driven pathways.
Methods Forty patients with type 2 diabetes (HbA1c 7.8±0.2% [62.1±2.3 mmol/mol]) and increased albumin-to-creatinine ratio (ACR) were randomized to fasting-mimicking diet (FMD) (n=21) or Mediterranean diet (n=19) for six months with three-month follow-up. Primary endpoint was the difference of the change in ACR from baseline to after six months between study groups. Subgroup analysis for patients with micro-versus macroalbuminuria at baseline was performed. Secondary endpoints comprised HOMA-IR, circulating markers of dicarbonyl detoxification (MG-H1, glyoxalase-1 and hydroxyacetone), lipid oxidation (acylcarnitines), DNA-damage/repair, (yH2Ax) and senescence (suPAR). Comparison was done by ANCOVA adjusted for age, sex, weight loss and baseline values of the respective outcome.
Results Difference of change in ACR between FMD and control group after six months was 110.3mg/g (95% CI 99.2, 121.5mg/g; P=0.45) in all patients, -30.3mg/g (95% CI -35.7, -24.9mg/g; P≤0.05] in patients with microalbuminuria, and 434.0mg/g (95% CI 404.7, 463.4mg/g; P=0.23) in those with macroalbuminuria at baseline. FMD led to change in HOMA-IR of -3,8 (95% CI -5,6, -2.0; P≤0.05) and in suPAR of - 156.6pg/ml (95% CI -172.9, -140.4pg/ml; P≤0.05) after six months, while no change was observed in markers of dicarbonyl detoxification or DNA-damage/repair. Change in AC profile was related to patient responsiveness to ACR improvement. At follow-up only HOMA-IR reduction (−1.9 [95% CI -3.7, -0.1], P≤0.05) was sustained.
Conclusions When accompanied by intensive diabetes care, FMD improves microalbuminuria, HOMA-IR and suPAR levels. Lack of changes in markers of dicarbonyl detoxification and DNA-damage/repair might explain the relapse of albuminuria at follow-up.
Trial registration German Clinical Trials Register (Deutsches Register Klinischer Studien DRKS), DRKS-ID: DRKS00014287
Competing Interest Statement
The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work. L-Nutra, as funder of the fasting-mimicking diet used in this study, has no role in the design or conduct of the study nor in the preparation, review, or approval of the manuscript. V.L. is founder and shareholder of L-Nutra; his shares are destined to the Create Cures Foundation and other charitable and research organizations.
Clinical Trial
DRKS00014287
Funding Statement
This study was funded by the German Research Foundation (DFG) project number 236360313 (SFB 1118) and project number 255156212 (SFB 1158) as well as by the German Center for Diabetes Research (DZD) project number 82DZD07C2G. The FMD diet used in this study was funded by L-Nutra. All funding bodies had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the University Hospital of Heidelberg approved all study procedures (Ethic-Nr. S-682/2016) in compliance with national guidelines and the declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data generated in this study are subject to national data protection laws and are available from the corresponding author upon reasonable request.
- Abbreviations
- AC
- acylcarnitines
- ACR
- albumin-to-creatinine ratio
- C2
- acetylcarnitine
- CTCAE
- common terminology criteria for adverse events
- DKD
- diabetic kidney disease
- FMD
- fasting-mimicking diet
- FPG
- fasting plasma glucose
- Glo-1
- glyoxalase-1
- MDS
- Mediterranean diet score
- MG
- methylglyoxal
- MG-H1
- methylglyoxal-derived hydroimidazolone 1
- RBC
- red blood cells
- PHQ
- patient health questionnaire
- SF-12
- 12-item short-form health survey questionnaire
- SGLT2
- sodium-glucose cotransporter-2
- pGlo-1
- phosphorylated glyoxalase-1
- WBC
- white blood cells
